R

Read Gene SA
WSE:RDG

Watchlist Manager
Read Gene SA
WSE:RDG
Watchlist
Price: 5.46 PLN Market Closed
Market Cap: 64.4m PLN

Operating Margin
Read Gene SA

-1.5%
Current
-5%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.5%
=
Operating Profit
-229.9k
/
Revenue
15.2m

Operating Margin Across Competitors

No Stocks Found

Read Gene SA
Glance View

Market Cap
64.4m PLN
Industry
Biotechnology

Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

RDG Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.5%
=
Operating Profit
-229.9k
/
Revenue
15.2m
What is the Operating Margin of Read Gene SA?

Based on Read Gene SA's most recent financial statements, the company has Operating Margin of -1.5%.

Back to Top